A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)

NCT06721143 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease Stage 3

Interventions

BIOLOGICAL: AION-301
DRUG: Placebo

Sponsor

AION Healthspan, Inc.

Collaborators

[object Object]